Incyclix Bio is a company working on advanced cancer treatments. They are developing a new drug called INX-315, a potent and selective inhibitor targeting CDK2, a protein that regulates the cell cycle. This drug aims to treat severe and resistant types of cancer.
Recently, Incyclix Bio received an additional $11.25 million in funding as part of its Series B financing round. This extension of funding comes from investors including Eshelman Ventures, Eli Lilly, Pharmacosmos, and a new investor, Cape Fear BioCapital. The additional funding will help support ongoing clinical trials for INX-315.
One of these trials is called INX-315-01, a Phase 1/2 study designed to test the safety and effectiveness of the drug in humans. This trial is now underway and involves carefully increasing the dose to see how the body handles the drug and to observe any preliminary anti-cancer effects.
The study is open-label, meaning that both researchers and patients are aware of the treatment being administered. It involves patients with advanced cancers that have resisted other treatments, including certain types of breast cancer that are resistant to hormone therapy and tumors with specific genetic features like CCNE1 amplification.
Incyclix Bio has shared early clinical data from the dose-escalation part of the study at the 2024 San Antonio Breast Cancer Symposium. The company expects to complete the study by mid-2026, which could lead to a new treatment option for difficult-to-treat cancers.
KEY QUOTES:
“This additional funding is a validation of the best-in-class potential of INX-315, and we are grateful for the continued support to advance our clinical trial, which could address the unmet needs of patients with advanced, treatment-resistant breast and ovarian cancers. With the additional capital, we’re positioned to complete this critical study and unlock key milestones that bring us closer to delivering precision treatments to patients.”
Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder of Incyclix Bio
“INX-315 has shown the promise of CDK2 as a meaningful target in treating patients with resistant forms of breast and ovarian cancer. We’re excited to continue supporting Incyclix’s knowledgeable and dynamic team as they bring this promising therapy through the clinic.”
Fred Eshelman, Co-Founder and Chairman of the Board and founder of Eshelman Ventures
